Small Cell Lung Cancer Immunotherapy: ASCO Tumor Boards

This is a case-based activity that includes discussion of a 71-year-old male who presented to the clinic with significant weight loss, cough, significant bilateral upper limb weakness, and double vision. He is a heavy former smoker with a two pack-per-day history of 60 years. Work up includes a CT of the thorax and biopsy of the supraclavicular lymph node.

Learning Objectives

  • Discuss the diagnostic approach and landscape of therapeutic options for patients with advanced small cell lung cancer
  • Review the emerging actionable alterations and emerging targets in small cell lung cancer
  • Interpret the data related to PD-1 based immunotherapy in patients with advanced small cell lung cancer
  • Recognize potential clinical applications for PD-1 based immunotherapy and management of common side effects

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Notes

  • This course expires on March 22, 2020. Participants must complete all necessary course components by this date to receive credit. 
  • This course is also available as part of the 2017 ASCO Tumor Boards bundle.